A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.

被引：0

作者：

Segal, Neil Howard

Hodi, F. Stephen

Sanborn, Rachel E.

Gajewski, Thomas

Wolchok, Jedd D.

Urba, Walter John

Fox, Bernard A.

Topallan, Suzanne Louise

Pardoll, Drew M.

Kollia, Georgia

McDonald, Dan

Kim, Su Young

Sharfman, William Howard

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Earle A Chiles Res Inst & Providence Canc Ctr, Portland, OR USA

[3] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA

[4] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[5] Bristol Myers Squibb Co, Princeton, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS3115

引用

页数：1

共 50 条

[41] NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Antonia, Scott J.
Rizvi, Naiyer A.
Chow, Laura Q.
Borghaei, Hossein
Brahmer, Julie R.
Juergens, Rosalyn
Shepherd, Frances A.
Laurie, Scott A.
Gerber, David E.
Goldman, Jonathan
Shen, Yun
Harbison, Christopher
Chen, Allen C.
Gettinger, Scott
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S153 - S153
[42] SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL)
Kluger, H.
Sznol, M.
Callahan, M.
Postow, M.
Gordon, R.
Segal, N. H.
Rizvi, N.
Lesokhin, A.
Atkins, M. B.
Kirkwood, J.
Burke, M.
Ralabate, A.
Rivera, A.
Kronenberg, S.
Agunwamba, B. U.
Feely, W.
Hong, Q.
Krishnan, S.
Wolchok, J.
ANNALS OF ONCOLOGY, 2014, 25
[43] Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.
Rizvi, Naiyer A.
Chow, Laura Quan Man
Borghaei, Hossein
Shen, Yun
Harbison, Christopher
Alaparthy, Suresh
Chen, Allen C.
Gettinger, Scott N.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[44] Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
Sznol, Mario
Kluger, Harriet M.
Callahan, Margaret K.
Postow, Michael Andrew
Gordon, Ruth Ann
Segal, Neil Howard
Rizvi, Nalyer A.
Lesokhin, Alexander M.
Atkins, Michael B.
Kirkwood, John M.
Burke, Matthew M.
Ralabate, Amanda L.
Rivera, Angel L.
Kronenberg, Stephanie Anne
Agunwamba, Blessing
Feely, William
Hong, Quan
Krishnan, Suba
Gupta, Ashok Kumar
Wolchok, Jedd D.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[45] Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
Sznol, Mario
Kluger, Harriet M.
Callahan, Margaret K.
Postow, Michael Andrew
Gordon, Ruth Ann
Segal, Neil Howard
Rizvi, Naiyer A.
Lesokhin, Alexander M.
Atkins, Michael B.
Kirkwood, John M.
Burke, Matthew M.
Ralabate, Amanda L.
Rivera, Angel L.
Kronenberg, Stephanie Anne
Agunwamba, Blessing
Feely, William
Hong, Quan
Krishnan, Suba
Gupta, Ashok Kumar
Wolchok, Jedd D.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18)
[46] EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL
Gettinger, Scott
Horn, Leora
Antonia, Scott J.
Spigel, David R.
Gandhi, Leena
Sequist, Lecia V.
Sankar, Vindira
Ahlers, Christoph M.
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok
Brahmer, Julie R.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S909 - S909
[47] Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.
Brahmer, Julie R.
Horn, Leora
Gandhi, Leena
Spigel, David R.
Antonia, Scott Joseph
Rizvi, Naiyer A.
Powderly, John D.
Heist, Rebecca Suk
Carvajal, Richard D.
Jackman, David Michael
Sequist, Lecia V.
Smith, David C.
Leming, Philip D.
Topalian, Suzanne Louise
Hodi, F. Stephen
Sznol, Mario
Harbison, Christopher
Kollia, Georgia
Gupta, Ashok Kumar
Gettinger, Scott N.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[48] A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice in advanced melanoma patients progressing post anti-CTLA-4 therapy.
Chmielowski, Bartosz
Hamid, Omid
Minor, David R.
D'Angelo, Sandra P.
Pennock, Gregory K.
Grossmann, Kenneth
Ascierto, Paolo Antonio
Daud, Adil
Dummer, Reinhard
Hodi, F. Stephen
Lebbe, Celeste
Robert, Caroline
Sosman, Jeffrey Alan
Yang, Arvin
Lambert, Alexandre
Weber, Jeffrey S.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[49] Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC).
Nishio, Makoto
Hida, Toyoaki
Nakagawa, Kazuhiko
Sakai, Hiroshi
Nogami, Naoyuki
Atagi, Shinji
Takahashi, Toshiaki
Nokihara, Hiroshi
Saka, Hideo
Takenoyama, Mitsuhiro
Fujita, Shiro
Tanaka, Hiroshi
Takeda, Koji
Satouchi, Miyako
Isobe, Hiroshi
Maemondo, Makoto
Goto, Koichi
Hirashima, Tomonori
Minato, Koichi
Tamura, Tomohide
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[50] A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
Robert, Caroline
Ascierto, Paolo Antonio
Maio, Michele
Hernberg, Micaela
Schmidt, Henrik
Waxman, Ian
Garbe, Claus
Lebbe, Celeste
Hauschild, Axel
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →